Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market to Reach $15.4 Billion by 2029 | Key Drivers and Future Outlook
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#What Is the Estimated Market Size of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market In 2029?#_x000D_
The market size for sodium glucose cotransporter 2 (SGLT2) inhibitors has significantly expanded in the past few years. From being valued at $10.17 billion in 2024, it is projected to escalate to $11.07 billion in 2025, representing a compound annual growth rate (CAGR) of 8.8%. Factors contributing to the previous period’s growth include successful early stage clinical trails, an uptick in regulatory approvals, an increase in the diagnosis of diabetes, and the growing demand for groundbreaking treatments for diabetes._x000D_
_x000D_
#What Growth Rate Is Forecasted for the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market by 2029?#_x000D_
The market size for sodium glucose cotransporter 2 (SGLT2) inhibitors is poised to experience robust expansion in the upcoming years. By 2029, it is projected to reach $15.4 billion, progressing at a compound annual growth rate (CAGR) of 8.6%. Factors contributing to growth in the prediction period include surging incidence of diabetes, escalating rates of obesity, heightened awareness about managing diabetes, and broadening use in treating heart and kidney diseases. The forecast period is expected to witness trends such as the incorporation of combination therapies, personalized medicine tactics, advances in technology, and conventional drug development._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp_x000D_
_x000D_
#Which Key Companies Are Shaping the Future of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?#_x000D_
Major companies operating in the sodium glucose cotransporter 2 (SGLT2) inhibitors market are Pfizer Inc., Johnson & Johnson Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmBH, Astellas Pharma Inc, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co. Ltd., Taisho Pharmaceutical Holdings Co. Ltd., Lupin Limited, Glenmark pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei Pharmaceutical Co. Ltd., Patsnap Synapse, Kotobuki Pharmaceutical Co Ltd._x000D_
_x000D_
#Which Factors Are Driving Demand in the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Industry?#_x000D_
The rising incidence of diabetes is anticipated to drive the expansion of the sodium glucose cotransporter 2 (SGLT2) inhibitor market. Diabetes is a set of metabolic diseases marked by elevated blood sugar, caused by irregularities in insulin secretion, insulin function, or both. Urbanization, stress, environmental contaminants, and limited healthcare accessibility are among the elements contributing to the surge in diabetes cases. Sodium glucose cotransporter 2 (SGLT2) inhibitors, which can decrease blood glucose levels by stopping glucose reabsorption in the kidneys, thereby leading to its removal through urine, are employed to treat diabetes. They also provide cardiovascular and renal benefits, rendering them an effective strategy for diabetes management and its associated complications. For instance, as reported by the Australian Bureau of Statistics in December 2023, around 5.3% of Australians, or nearly 1.3 million individuals, were diagnosed with diabetes in 2022, with similar rates in men (5.8%) and women (4.9%). Diabetes incidence has been steadily on the rise, noticeably increasing with age, and peaks at 18.7% in individuals aged 75 and above. Type 2 diabetes is the most prevalent, making up 87.6% of cases. Aspects such as foreign birth, residency in disadvantaged regions, and disabilities are linked to higher diabetes incidence. As a result, the escalating incidence of diabetes is propelling the sodium glucose cotransporter 2 (SGLT2) inhibitor market’s growth._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=18473&type=smp_x000D_
_x000D_
#How Is the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Segmented by Several Divisions?#_x000D_
The sodium glucose cotransporter 2 (SGLT2) inhibitors market covered in this report is segmented –_x000D_
_x000D_
1) By Type: Invokana, Jardiance, Farxiga Or Forxiga, Suglat_x000D_
2) By Route Of Administration: Oral Route, Other Route Of Administration_x000D_
3) By End User: Hospitals, Homecare Settings, Clinics_x000D_
_x000D_
Subsegments:_x000D_
1) By Invokana: Generic Invokana (Canagliflozin), Branded Invokana_x000D_
2) By Jardiance: Generic Jardiance (Empagliflozin), Branded Jardiance_x000D_
3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin), Branded Farxiga_x000D_
4) By Suglat: Suglat (Sotagliflozin) For Diabetes, Suglat (Sotagliflozin) For Heart Failure_x000D_
_x000D_
_x000D_
#What are the Emerging Market Trends Driving the Growth of the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Industry?#_x000D_
Leading businesses within the sodium glucose cotransporter 2 (SGLT2) inhibitor market are channeling their efforts towards the development of dual inhibitor therapeutic treatments in an effort to enhance patient results and regulate blood sugar levels. These treatments work by simultaneously targeting SGLT1 and SGLT2, two different sodium-glucose cotransporters, to provide more effective management of conditions like diabetes and heart failure. In an illustrative case, Lexicon Pharmaceuticals Inc., a biopharmaceutical company headquartered in the United States, was granted approval in May 2023 by the Food and Drug Administration (FDA) for their heart failure treatment, sotagliflozin. This pioneering dual inhibitor of sodium-glucose cotransporters 1 and 2, comes in a once-daily tablet form and aims to decrease cardiovascular fatalities, hospitalizations due to heart failure, and urgent visits for heart failure in adults having heart failure, type 2 diabetes, chronic kidney disease, along with other cardiovascular risk factors. Its unique feature is the ability to decrease renal glucose and sodium reabsorption, thereby reducing preload and afterload, and curtailing sympathetic activity._x000D_
_x000D_
#Access The Full Report Here:#_x000D_
_x000D_
#Which Regions Are Driving Growth in the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?#_x000D_
North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Purchase The Full Report Today:#_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18473_x000D_
_x000D_
#This Report Delivers Insight On: #_x000D_
1. How big is the sodium glucose cotransporter 2 (sglt2) inhibitors market, and how is it changing globally?_x000D_
2. Who are the major companies in the sodium glucose cotransporter 2 (sglt2) inhibitors market, and how are they performing?_x000D_
3. What are the key opportunities and risks in the sodium glucose cotransporter 2 (sglt2) inhibitors market right now?_x000D_
4. Which products or customer segments are growing the most in the sodium glucose cotransporter 2 (sglt2) inhibitors market?_x000D_
5. What factors are helping or slowing down the growth of the sodium glucose cotransporter 2 (sglt2) inhibitors market?_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 2071930708_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
